Pfizer

Pfizer's reported carbon emissions

Pfizer, a prominent pharmaceutical preparation manufacturer based in the US, has detailed climate commitments and emissions data. For the reporting year 2022, Pfizer reported a total of approximately 93.78 billion kg CO2e for Scope 3 emissions. This encompassed substantial contributions from purchased goods and services, which amounted to roughly 8.25 billion kg CO2e, and fuel and energy-related activities at approximately 263 million kg CO2e. Scope 1 emissions for the same year were about 644.57 million kg CO2e, while Scope 2 emissions (market-based) were approximately 483.28 million kg CO2e. Looking at more recent reporting periods, for the reporting year 2025 (as of the latest data available for this year), Pfizer has reported Scope 3 emissions for business travel at about 175 million kg CO2e and upstream transportation and distribution at approximately 110 million kg CO2e. Scope 1 and 2 emissions for this reporting year were approximately 750 million kg CO2e. Pfizer has established ambitious climate targets, including a near-term goal to reduce absolute Scope 1 and 2 greenhouse gas (GHG) emissions by 46% by 2030, using a 2019 baseline. This target is aligned with a 1.5°C trajectory and has been approved by the Science Based Targets initiative (SBTi). Furthermore, Pfizer aims to achieve Net-Zero emissions across its value chain by 2040. As part of its commitment to renewable energy, the company aims to procure 100% renewable electricity by 2030. In addition to these overarching goals, Pfizer has specific commitments for Scope 3 emissions. This includes a target to reduce emissions from upstream transportation and distribution by 10% by 2025, also from a 2019 baseline. For business travel, the company aims for a 25% reduction in Scope 3 emissions by 2025, again from a 2019 baseline. Pfizer also has a commitment that by 2025, 64% of its suppliers, by spend covering purchased goods and services, will have set their own science-based GHG reduction targets.